A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib

In the last two decades, simultaneous global development of novel drugs become more common by conducting multiregional clinical trials. However, regulatory authorities of different regions often make different decisions on the approvals of the same new drugs. We would like to discuss the appropriateness of Japanese regulatory approach through a case study of quizartinib, a novel anti-leukemia drug developed in Japan. The pivotal clinical trial “QuANTUM-R” conducted in 19 countries showed a modest increase in median overall survival with quizartinib than the conventional chemotherapy. However, because several critical defects in this trial were pointed out by the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA), quizartinib has not been approved in the US and Europe to date. On the contrary, the regulatory authority of Japan gave a notice of approval to quizartinib as a “standard of care”, and the country becomes the sole country that granted market authorization. In our paper, we provide more detailed discussion about the methodology for scientific evaluation of the new drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Rent this article via DeepDyve

Similar content being viewed by others

Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials

Article 03 March 2020

Oncology drug lag in Japan: has it improved over the last decade?

Article 10 August 2023

Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan

Article 17 April 2018

Availability of data and material

Not applicable. This manuscript does not include any experimental data or material.

References

  1. Watanabe A, Chang SC, Kim MJ, Chu DWS, Ohashi Y (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51(10):1167–1175. https://doi.org/10.1086/656802ArticleCASPubMedGoogle Scholar
  2. Cyranoski D (2019) The potent effects of Japan’s stem-cell policies. Nature 573:482–485. https://doi.org/10.1038/d41586-019-02847-3ArticleCASPubMedGoogle Scholar
  3. Tanimoto T, Tsubokura M, Mori J, Pietrek M, Ono S, Kami M (2013) Differences in drug approval processes of 3 regulatory agencies: A case study of gemtuzumab ozogamicin. Invest New Drugs 31(2):473–478. https://doi.org/10.1007/s10637-012-9877-8ArticlePubMedGoogle Scholar
  4. Larrosa-Garcia M, Baer MR (2017) FLT3 Inhibitors in acute myeloid leukemia: Current status & future directions. Mol Cancer Ther 16(6):991–1001. https://doi.org/10.1158/1535-7163.MCT-16-0876ArticleCASPubMedPubMed CentralGoogle Scholar
  5. Cortes JE, Khaled S, Martinelli G et al (2019) Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20(7):984–997. https://doi.org/10.1016/S1470-2045(19)30150-0ArticleCASPubMedGoogle Scholar
  6. US Food & Drug Administration, Advisory committee meeting (2019) https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-14-2019-meeting-oncologic-drugs-advisory-committee-meeting-announcement-05142019-05142019. Accessed 16 Feb 2021
  7. ASH Clinical News (2019) Mixed opinions on quizartinib from the FDA and Japanese regulators. https://www.ashclinicalnews.org/news/latest-and-greatest/mixed-opinions-quizartinib-fda-japanese-regulators/. Accessed 16 Feb 2021
  8. Targeted Oncology (2019). Complete response letter issued by FDA for quizartinib NDA in AML. https://www.targetedonc.com/view/complete-response-letter-issued-by-fda-for-quizartinib-nda-in-aml. Accessed 16 Feb 2021
  9. Report of Deliberation (2019) Pharmaceutical Evaluation and Control Division, Pharmaceutical and Life Sciences Bureau (article in Japanese). https://www.pmda.go.jp/drugs/2019/P20190628001/430574000_30100AMX00017_A100_1.pdf. Accessed 16 Feb 2021
  10. Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642–4649. https://doi.org/10.1200/JCO.2003.04.036ArticlePubMedGoogle Scholar

Author information

Authors and Affiliations

  1. Saga-Ken medical centre KOSEIKAN, Department of Hematology, Saga, Japan Keisuke Kidoguch
  2. Department of Hematology, Shinmatsudo Central General Hospital, Chiba, Japan Motoharu Shibusawa
  3. Navitas Clinic Kawasaki, Kanagawa, Japan Tetsuya Tanimoto
  1. Keisuke Kidoguch